LiDCO provided a strong H1 trading update, with revenues up 75% to £6.2m driven by strong growth in capital monitor sales (+c.340%) and HUP licence revenue (+83%), which offset a decline in smartcard sales because of lower elective surgeries due to COVID. Although it is not clear how quickly elective surgery rates will rebound to pre-COVID levels, there is evidence to indicate that in Q2, they recommenced in the US and LiDCO’s commercial teams were able to visit customer sites. On
24 Aug 2020
LiDCO - Six-month trading update drives further upgrade
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
LiDCO - Six-month trading update drives further upgrade
- Published:
24 Aug 2020 -
Author:
Mark Brewer | Cavendish Research -
Pages:
8
LiDCO provided a strong H1 trading update, with revenues up 75% to £6.2m driven by strong growth in capital monitor sales (+c.340%) and HUP licence revenue (+83%), which offset a decline in smartcard sales because of lower elective surgeries due to COVID. Although it is not clear how quickly elective surgery rates will rebound to pre-COVID levels, there is evidence to indicate that in Q2, they recommenced in the US and LiDCO’s commercial teams were able to visit customer sites. On